Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin

Enfortumab vedotin is an antibody–drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Thibodeau, Alexa, Nallasamy, Nambi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493475/
https://www.ncbi.nlm.nih.gov/pubmed/34629907
http://dx.doi.org/10.2147/IMCRJ.S324394
_version_ 1784579121471291392
author Thibodeau, Alexa
Nallasamy, Nambi
author_facet Thibodeau, Alexa
Nallasamy, Nambi
author_sort Thibodeau, Alexa
collection PubMed
description Enfortumab vedotin is an antibody–drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Enfortumab vedotin is not previously known to cause cataract development or progression and, thus, our patient’s presentation may reflect the first report of an undocumented adverse effect of this novel agent.
format Online
Article
Text
id pubmed-8493475
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84934752021-10-07 Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin Thibodeau, Alexa Nallasamy, Nambi Int Med Case Rep J Case Report Enfortumab vedotin is an antibody–drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Enfortumab vedotin is not previously known to cause cataract development or progression and, thus, our patient’s presentation may reflect the first report of an undocumented adverse effect of this novel agent. Dove 2021-10-01 /pmc/articles/PMC8493475/ /pubmed/34629907 http://dx.doi.org/10.2147/IMCRJ.S324394 Text en © 2021 Thibodeau and Nallasamy. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Thibodeau, Alexa
Nallasamy, Nambi
Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
title Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
title_full Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
title_fullStr Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
title_full_unstemmed Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
title_short Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
title_sort bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493475/
https://www.ncbi.nlm.nih.gov/pubmed/34629907
http://dx.doi.org/10.2147/IMCRJ.S324394
work_keys_str_mv AT thibodeaualexa bilateralanteriorsubcapsularcataractdevelopmentfollowinginitiationofenfortumabvedotin
AT nallasamynambi bilateralanteriorsubcapsularcataractdevelopmentfollowinginitiationofenfortumabvedotin

Ejemplares similares